Home/Pipeline/AGILE 3

AGILE 3

Risk of rapid progression in early Chronic Kidney Disease (CKD)

ApprovedActive

Key Facts

Indication
Risk of rapid progression in early Chronic Kidney Disease (CKD)
Phase
Approved
Status
Active
Company

About numares

Numares AG is a pioneering diagnostics company leveraging a unique combination of NMR spectroscopy and artificial intelligence to analyze blood metabolites. Its core technology, the AXINON® platform, is designed to identify complex disease signatures, moving beyond single biomarkers to enable earlier and more accurate diagnosis of conditions like chronic kidney disease and cardiovascular disorders. As a private company, Numares has progressed key assays through regulatory pathways, positioning itself in the high-growth precision diagnostics market. Its strategy involves both developing its own diagnostic tests and partnering with pharmaceutical companies for companion diagnostics.

View full company profile